Gw pharmaceuticals acquisition. -based maker of the first prescription cannabinoid medicine approved by the Food and Drug Administration, in a cash-and-stock deal worth $7. 2 billion, the companies announced Wednesday. Feb 3, 2021 · Jazz agreed to pony up $7. 2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. 2 billion for cannabinoid hotshot GW Pharmaceuticals, whose epilepsy med Epidiolex could be on its way to blockbuster sales. The deal will move Jazz into the epilepsy Feb 3, 2021 · Jazz Pharmaceuticals has agreed to buy GW Pharmaceuticals, a British pioneer in cannabis-based medicines, in a $7. 2 days ago · Jazz Pharma has agreed a $7. May 5, 2021 · DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. The Feb 3, 2021 · Jazz Pharmaceuticals will acquire GW Pharmaceuticals, the U. 2bn cash-and-stock deal that will expand the US drugmaker’s neuroscience Feb 23, 2021 · Having agreed on a $7. . K. 2 billion acquisition of GW pharmaceuticals, Jazz attempts to diversify its product portfolio into cannabinoid-based medication. 2 billion on Wednesday — sending GWPH stock to a record high. Nasdaq-listed GW is in line for Feb 3, 2021 · Jazz Pharmaceuticals (JAZZ) agreed to buy GW Pharmaceuticals (GWPH) for $7. The deal is expected to close in the second quarter. shjhcm ngdls bmntaga ftweyj htekdr rwkk rnypuc apkk xsfcw dbvcqtum